

## RECEIVED

AUG 2 0 2001 #36

plus sign (+) inside this box

TECH CENTER 4600/4990 Approved for use thro Please type plus sign (+) inside this box

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRADE The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 08/765,695 INFORMATION DISCLOSURE Filing Date July 25, 1997 STATEMENT BY APPLICANT First Named Inventor Lars Abrahmsen Group Art Unit 1644 (use as many sheets as necessary) **Examiner Name** R. Schwadron of P01525US0/09804877 1 Attorney Docket Number Sheet

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code <sup>2</sup> (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

				FOREIC	IN PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Batantas as	Bata of Bultivation of	Pages, Columns, Lines,	Т
		Office <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Τ°

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
135	Α	JARDETZKY, THEODORE S., et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen; <i>Nature</i> Vol. 368, p. 711-718 (1994)			
Mi	В	KIM, JONGSUN, et al. Toxic Shock Syndrome Toxin-1 Complexed with a Class II Major Histocompatibility Molecule HLA-DR1; <i>Science</i> Vol. 266, p. 1870-1874 (1994)			

Examiner Signature	Date Considered 113/200

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. \*5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.